When you go to “COOKIES INCL. ALLOW US SERVICES” click, you agree to the storage of cookies on your device to improve website navigation, analyze site usage, and support our marketing efforts. For more information, see our Privacy statement.

8.11.2023

Monovisc® approved for extended Areas of Application in the EU

Monovisc® has now been approved in the EU for extended areas of application (hip, shoulder and ankle)!

The product Monovisc®, an injection for the treatment of joint pain that was recently approved for extended applications in the EU, in front of packaging on a white background.

Big news from Anika! Monovisc® has been officially approved in the EU for use not only in knees but also in hip, shoulder and ankle joints. This significant expansion is based on extensive clinical studies and is fantastic news for patients who can now benefit from Monovisc®'s proven pain relief in various joints.

The adjustments in the Instructions for use (IFU) may still take some time. However, the electronic user manual (eIFU) is updated and published faster than the paper version. The application of Monovisc for this indications is from now on in EU countries potential.

As soon as the Package insert is updated, it will read as follows:


Monovisc is indicated as a viscoelastic supplement or a replacement for synovial fluid in human knee, hip, shoulder and ankle joints. Monovisc is well suited for treatment of the symptoms of mild to moderate osteoarthritis of the knee, hip, shoulder, and ankle joints for patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics. In clinical studies, Monovisc has been proven to have a duration of effect of at least 6 months and a second injection 6 months after the first injection was shown to be safe.

To the MONOVISC® product page

Für weitere Informationen kontaktieren Sie bitte:

More posts

Event

Review: Successful start of the QKG basic course “Cartilage Specialists” in Graz

Successful basic QKG course in Graz: Current developments in cartilage therapy.
Product Update

HyaloFast® receives MDR certification

Hyalofast® receives MDR approval and sets new standards in cartilage regeneration.
Event

Knee+Ski 2025 — expert knowledge and innovations in knee surgery

The premiere of the Knee+Ski Congress took place in Fieberbrunn from February 19 to 23, 2025.

Make evidence-based decisions

Learn more about our scientifically researched products. Please feel free to contact us for further information.